New cancer drug begins early human testing
NCT ID NCT06238401
Summary
This is an early-stage study to test the safety and find the right dose of a new drug called ACR246 for people with advanced solid tumors. It will involve about 77 adults whose cancer has continued to grow despite standard treatments. The main goal is to see how well the drug is tolerated and to understand how it moves through the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tumor Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shandong First Medical University affiliated Cancer Hospital of Shandong
RECRUITINGShandong, Jinan, 250117, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
ShangHai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, 200030, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
ShangHai Sixth People's Hospital
RECRUITINGShanghai, Shanghai Municipality, 200233, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhejiang Cancer Hospital
RECRUITINGZhejiang, Hangzhou, 310022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.